Navigation Links
Marinus Pharmaceuticals Issued Patent for Ganaxolone
Date:4/7/2011

NEW HAVEN, Conn., April 7, 2011 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., the leader in development of neurosteroids for central nervous system disorders, today announced that the United States Patent and Trademark Office (USPTO) issued the company Patent Number 7,858,609 entitled, "Solid ganaxolone formulations and methods for the making and use thereof." The patent describes a novel class of small molecules to improve stability and bioavailability of nanoparticulate formulations of ganaxolone and will provide coverage until the end of 2026.

“Neurosteroids like ganaxolone have been difficult to formulate in the past because of differences in exposure that are dependent on the dose and amount of food in the stomach,” commented Kenneth Shaw, Ph.D., Senior Vice President, R&D at Marinus. “Marinus’ discovery of a novel class of stabilizing agents has produced new nanoparticulate formulations of ganaxolone that appear to be superior to historical formulations in minimizing these differences.”

The company has submitted a second patent application covering a new synthesis method for ganaxolone that decreases the number of process steps thus increasing cost efficiency.

About Ganaxolone

Ganaxolone is a synthetic neurosteroid and a derivative of the naturally occurring neuromodulator, allopregnanolone.  Ganaxolone has been administered to more than 950 healthy adult volunteers and patients in Phase 1 and Phase 2 studies. Completed Phase II epilepsy studies have generated data supportive of the efficacy and safety of ganaxolone in the treatment of both children and adults suffering from refractory epilepsy (patients who continue to have seizures despite taking multiple anticonvulsant drugs). Scientific research has suggested that ganaxolone therapy may be useful in the treatment of several other central nervous system disorders including posttraumatic stress disorder (PTSD) and Fragile-X syndrome (FXS). Ganaxolone is being developed as a first in class treatment in epilepsy, PTSD and FXS.

Marinus has successfully developed several proprietary and novel patented formulations of ganaxolone.

About Marinus Pharmaceuticals

Marinus is a specialty pharmaceutical company dedicated to the reformulation, development, and commercialization of novel drugs to treat serious neurological and psychiatric disorders. Marinus is located in Branford, Connecticut. Its investors include Domain Associates, Canaan Partners, Sofinnova Ventures and Foundation Medical Partners. For additional information, please visit the company’s Web site at www.marinuspharma.com.


'/>"/>
SOURCE Marinus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cempra Pharmaceuticals to Present at Two Upcoming Cambridge Healthtech Institute (CHI) Conferences
2. Reportlinker Adds Global: Pharmaceuticals Industry Guide
3. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
4. Valeant Pharmaceuticals Files Preliminary Consent Solicitation Statement With the SEC
5. Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Raises Target Price to $3.22
6. Avanir Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
7. Trading Halted Today in Optimer Pharmaceuticals Stock
8. Cumberland Pharmaceuticals Appoints Rick S. Greene as Vice President, Finance & Accounting
9. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011
10. Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session
11. Dipexium Pharmaceuticals Updates Locilex™ Development Activities and Announces 2011 Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... IRVINE, Calif., Feb. 11, 2016 PRO-DEX, INC. (NasdaqCM: ... quarter ended December 31, 2015. The Company also filed its ... fiscal year 2016 with the Securities and Exchange Commission today. ... December 31, 2015 --> --> ... 2015 increased $2.6 million, or 95%, to $5.4 million from ...
(Date:2/11/2016)... has committed to provide drug disposal kiosks in ... as part of a program to combat drug ... organization As You Sow. Conrad MacKerron , Senior ... to unneeded drugs because they lack easily accessible collection and ... Conrad MacKerron , Senior Vice President at As You ...
(Date:2/11/2016)... -- Potrero Medical, Inc., the developer of the Accuryn™ critical ... George M. Rapier, III , MD, to its Board ... WellMed is one of the nation,s largest physician owned practice ... Texas and Florida ... internal medicine practice, he has been instrumental to the company,s ...
Breaking Medicine Technology:
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... through a world of exterior design possibilities. CertainTeed, North America’s leading brand of ... by expanding the product offerings showcased in the mobile version of the ColorView® ...
(Date:2/12/2016)... ... ... Coast Autism Spectrum Center (CCASC) invites teens ages 11-18 to its annual Winter Teen Dance. ... and without special needs to gather in a safe and supportive environment. Volunteers will be ... place on Saturday, Feb. 13 from 7 to 9:30 p.m. at Elks Lodge, 322 Elks ...
(Date:2/12/2016)... ... 2016 , ... Planet Future is a Final Cut Pro X ... for showcasing pictures, videos as well as text in an exciting cartoon environment. Planet ... and a beautiful frame overlay. Pixel Film Studios makes editing easy; simply insert media ...
(Date:2/11/2016)... ... February 11, 2016 , ... “ HEALING MIND : ... Well Managed Mind” (published by Balboa Press) teaches readers how to become their own ... profound love, author Janice McDermott, M.Ed., LCSW, offers an understanding of how to heal ...
(Date:2/11/2016)... Jersey (PRWEB) , ... February 11, 2016 , ... Registered ... a free CEU seminar titled, “Stroke Management: Time to Act, Time to Heal” on ... Community in Whippany, N.J. The presenter is Vishal Chedda, president of ANSA Consultants, ...
Breaking Medicine News(10 mins):